SEMAGLUTIDE

Brand name:

• Wegovy®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Established cardiovascular disease (eCVD) with obesity

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New PBS listing (–)

Comment:

--

Submission sponsor:

NOVO NORDISK PHARMACEUTICALS PTY. LIMITED

Other PBAC consideration:

• SEMAGLUTIDE

Submission received for:

November 2025 PBAC meeting

Opportunity for consumer comment:

Open 30/07/2025 and close 24/09/2025 (see PBS Website)

PBAC meeting:

Held on 05/11/2025

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

20/02/2026

5Lodgement of required documentation:

27/02/2026

Acceptance of complete documentation:

Under consideration

6Agreement to listing arrangements:

Has not yet commenced

7Government processes:

Has not yet commenced

8Medicine listed on the PBS:

Has not yet occurred

---